Withania somnifera (Ashwagandha) is one of the most venerated medicinal plant known for incredible pharmacological activities due to its active constituents like withanoloids, alkaloids, sitoindosides and flavonoids. Trials conducted with Ashwagandha have demonstrated its strong anticancer, antiinflammatory, neuroprotective and immunomodulating activity; however, its clinical use has been hampered mainly because of its poor aqueous solubility, low bioavailability; chemical instability in gastrointestinal track and rapid metabolism and elimination of the phytoconstituents present in it. Strategies of the nanoformulations have been applied as a promising solution to these obstacles with therapeutic effects. The review is centred around the recent progress in nanoformulation approaches of Ashwagandha bioactive components, which comprises polymeric nanoparticles, lipid-based nanocarriers, liposomes, phytosomes, nanoemulsions, self-nanoemulsifying systems and inorganic as well as hybrid nanocarriers. The application of targeted and stimuli-responsive nanoformulations for enhancing site-specific delivery and controlled release is also reviewed. Additionally, pharmaceutical so lutions, safety concerns, regulatory constraints and up-scaling problems are emphasized. Taken together, the nanoformulation strategies hold great promise in translation of Ashwagandha bioactives into efficacious, standardized and clinically scalable drug delivery systems. .